Hospital
Scottsdale Healthcare Hospitals
Scottsdale Healthcare Hospitals was paid $2.62M by Medicaid between Jan 2018 and May 2021, across 84 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoSCOTTSDALE HEALTHCARE HOSPITALS
PHOENIX, AZ 85085
PHOENIX, AZ 85085
33aNPI1821533274assigned 12/21/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.62M
24GClaims62,053
24DCodes billed84
24AFirst – last monthJan 2018 – May 2021
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#53 of 78
Median peer was paid$12.21M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,690 | $960K | |
| 2019 | 25,846 | $1.03M | |
| 2020 | 14,426 | $630K | |
| 2021 | 91 | $5K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 3,682 | 3,441 | $692K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 26% | 1,373 | 1,263 | $688K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 2,946 | 2,773 | $394K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 975 | 925 | $316K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.6% | 2,417 | 2,280 | $224K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.3% | 595 | 562 | $166K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 663 | 635 | $52K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.3% | 95 | 93 | $33K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 145 | 139 | $17K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 257 | 242 | $13K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 128 | 122 | $8K |
| 73564 | <1% | 68 | 67 | $7K |
72 more codes
| 76830 | Ultrasound, transvaginal | <1% | 25 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,140 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 19 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,321 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 176 | $931.36 |
| 80053 | Comprehensive metabolic panel | <1% | 2,977 | $221.71 |
| 93971 | <1% | 12 | $186.55 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 224 | $127.23 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,993 | $126.36 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,048 | $124.93 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 347 | $97.26 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,013 | $80.98 |
| 73630 | <1% | 40 | $49.62 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,419 | $38.43 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 839 | $36.21 |
| 90715 | <1% | 24 | $30.95 | |
| 73130 | <1% | 41 | $23.80 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,415 | $18.85 |
| 84703 | <1% | 1,160 | $10.74 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,759 | $1.24 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 345 | $1.10 |
| 81001 | 0% | 2,994 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 256 | $0.00 |
| 83690 | 0% | 1,886 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 273 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 321 | $0.00 |
| 96376 | 0% | 487 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 364 | $0.00 |
| 85027 | 0% | 282 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 383 | $0.00 |
| 85730 | 0% | 268 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 1,142 | $0.00 |
| 87077 | 0% | 81 | $0.00 | |
| 71045 | Radiologic examination, chest; single view | 0% | 1,124 | $0.00 |
| 87081 | 0% | 261 | $0.00 | |
| 83735 | 0% | 526 | $0.00 | |
| 83605 | 0% | 151 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 411 | $0.00 |
| 84484 | 0% | 1,412 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 291 | $0.00 |
| 87040 | 0% | 110 | $0.00 | |
| 85379 | 0% | 675 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 199 | $0.00 |
| 80320 | 0% | 76 | $0.00 | |
| 83880 | 0% | 44 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 12 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 55 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 12 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 12 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 13 | $0.00 |
| 81025 | 0% | 465 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 1,869 | $0.00 |
| 87631 | 0% | 69 | $0.00 | |
| 80306 | 0% | 276 | $0.00 | |
| 85610 | 0% | 1,126 | $0.00 | |
| 82248 | 0% | 1,121 | $0.00 | |
| 73562 | 0% | 13 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,485 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 322 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 1,018 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 507 | $0.00 |
| 73610 | 0% | 54 | $0.00 | |
| 73030 | 0% | 13 | $0.00 | |
| 85007 | 0% | 50 | $0.00 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 0% | 1,810 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 135 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 26 | $0.00 |
| 87400 | 0% | 700 | $0.00 | |
| 87186 | 0% | 43 | $0.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 0% | 124 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 12 | $0.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAPORTE, TODD (CEO)
| Provider | Location | Paid |
|---|---|---|
| Honorhealth | Scottsdale, AZ | $391K |
| Honorhealth | Scottsdale, AZ | $343K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.